The company is adding new products treating a range of issues, including HIV, hypertension and behavioral health.

The pharmacy benefit manager has removed reauthorization requirements for more than 140 drugs so far this year amid what ...

UnitedHealth's shares drop 40% in 2025 amid challenges, with mixed Q1 earnings and margin pressures ahead. Read why I rate ...

Optum Rx is nixing reauthorization requirements for more than 60 additional medications. | The PBM giant's list of drugs includes products for behavioral health, HIV, dry eye disease, high cholesterol ...

UnitedHealth stock outlook is in sharp focus as shares stay locked between $300 and $310. With Q2 earnings approaching and ...

The Federal Trade Commission (FTC), charged with protecting the American consumer, on January 15, 2025, issued a special ...

June has seen a slew of executive hires, promotions, exits and layoffs across the healthcare sector. For example, CVS Health ...

Optum Rx officials said they now have eliminated reauthorization requirements for more than 140 chronic disease medications.

From sprawling hospital systems to the growing influence of private equity, the physician landscape is shifting rapidly. Here are the top five players driving change — and controversy — in physician ...

From new executive appointments to expanded AI tools, here are 10 updates to know on UnitedHealth Group’s Optum, the parent company of ASC chain SCA Health, that Becker’s has reported on in the first ...

Patrick Conway, who recently became chief executive of the larger Optum health services division, will replace Dr. Amar Desai ...